Cela3b Antibody

What is CELA3B and where is it normally expressed?

CELA3B (also known as elastase-3B) is a pancreatic enzyme that serves digestive functions in the intestine. RNA analyses of normal tissues indicate that CELA3B expression is predominantly limited to the pancreas. Immunohistochemical studies show strong cytoplasmic CELA3B expression in all acinar cells of the pancreas and in a fraction of ductal cells. Additionally, distinct staining may be observed on the apical membranes of surface epithelial cells in the small intestine and colorectum, though at variable intensity and only in a subset of samples .

How specific is CELA3B expression to pancreatic tissue?

CELA3B exhibits extremely high tissue specificity. According to comprehensive tissue microarray studies analyzing 76 different normal tissue types, significant CELA3B immunostaining was observed exclusively in pancreatic acinar cells and some ductal cells. The protein was completely absent in numerous other tissues including striated muscle, heart muscle, smooth muscle, liver, kidney, respiratory epithelium, and various other organ systems . This remarkable specificity makes CELA3B an excellent pancreatic tissue marker.

Does CELA3B interact with other pancreatic enzymes?

Yes, CELA3B is known to interact closely with Carboxypeptidase A1 (CPA1) under physiological conditions. Research shows that proCELA3B forms complexes with proCPA1, which increases the binding activity of the inhibitory activation peptide of procarboxypeptidases, thereby stabilizing the zymogen state. This interaction is reflected in significant association between CELA3B and CPA1 expression patterns observed in acinar cell carcinomas .

What is the recommended protocol for CELA3B immunohistochemistry?

The validated protocol for CELA3B immunohistochemistry includes the following steps:

• Deparaffinize freshly cut tissue sections

• Perform heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH 7.8 buffer

• Apply primary CELA3B antibodies (e.g., rabbit recombinant, MS Validated Antibodies, MSVA-410M) at 37°C for 60 minutes at a 1:1800 dilution

• Visualize bound antibody using an appropriate detection system (e.g., EnVision Kit™)

• Estimate the percentage of positive neoplastic cells and record staining intensity semiquantitatively (0, 1+, 2+, 3+)

This protocol has been validated in large-scale studies involving thousands of tissue samples .

How should CELA3B immunostaining results be interpreted and quantified?

For accurate assessment of CELA3B immunostaining, results should be categorized into four groups:

• Negative: No staining observed

• Weakly positive: 1+ staining intensity in ≤70% of tumor cells or 2+ intensity in ≤30% of cells

• Moderately positive: 1+ staining intensity in >70% of cells, 2+ intensity in 31-70%, or 3+ intensity in ≤30%

• Strongly positive: 2+ intensity in >70% or 3+ intensity in >30% of cells

This semiquantitative scoring system allows for standardized interpretation across different laboratories and studies .

What controls should be included when using CELA3B antibody for research?

When conducting CELA3B immunohistochemistry, researchers should include:

• Positive control: Normal pancreatic tissue, which should show strong cytoplasmic staining in acinar cells

• Negative controls: Multiple non-pancreatic tissues that should show no CELA3B immunoreactivity

• Technical negative control: Primary antibody omission to assess background staining

Including these controls is essential for validating assay performance and ensuring reliable interpretation of experimental results .

What is the diagnostic utility of CELA3B immunohistochemistry for pancreatic cancers?

CELA3B immunohistochemistry has demonstrated exceptional utility for identifying acinar cell carcinoma of the pancreas, with a sensitivity of 75% and a specificity of 99.9%. In comprehensive studies analyzing 13,223 tumor samples from 132 different tumor types, CELA3B immunostaining was observed in 12 of 16 (75%) acinar cell carcinomas of the pancreas, including 6 cases with strong staining (37.5%). In contrast, only 5 of 13,207 other tumors (0.04%) showed any CELA3B positivity .

The following table summarizes CELA3B expression in acinar cell carcinoma compared to other tumor types:

This makes CELA3B antibody an invaluable tool for diagnosing this rare and often misclassified pancreatic cancer subtype .

Can CELA3B antibody help distinguish acinar cell carcinoma from other pancreatic neoplasms?

Yes, CELA3B immunohistochemistry can significantly aid in distinguishing acinar cell carcinoma from other pancreatic neoplasms, particularly neuroendocrine tumors and ductal adenocarcinomas. This distinction is clinically important yet challenging, as acinar cell carcinomas can display various architectural patterns beyond the classic acinar arrangement. Studies have shown that experts in gastrointestinal pathology frequently misclassify these rare tumors, with one retrospective analysis at Johns Hopkins identifying only 14 acinar cell carcinomas over an 18-year period .

CELA3B antibody, as part of a panel that may include other markers like CPA1, chymotrypsin, trypsin, or bcl10, can increase diagnostic precision for pancreatic acinar cell carcinoma .

Does CELA3B expression occur in any non-pancreatic tumors?

While extremely rare, CELA3B expression has been detected in a small subset of non-pancreatic tumors. Specifically, weak to moderate cytoplasmic granular staining was observed in:

• 1.2% of adenoid cystic carcinomas (of salivary glands)

• 1.2% of mucoepidermoid carcinomas (of salivary glands)

• 0.8% of acinic cell carcinomas (of salivary glands)

This limited cross-reactivity with certain salivary gland tumors may reflect the shared histological and functional features between salivary glands and pancreatic tissue, including their organization into ductal and acinar cells and their secretion of digestive enzymes .

How does CELA3B expression correlate with tumor differentiation and potential prognostic value?

Research indicates that reduced CELA3B expression in acinar cell carcinomas may reflect cellular de-differentiation. Studies have documented decreased CELA3B expression in pancreatic cancer cell lines and tissues compared to adjacent normal pancreatic tissues. This reduction in CELA3B (and associated CPA1) expression could potentially be linked to unfavorable patient prognosis, though more extensive clinical correlation studies are needed to establish definitive prognostic significance .

The correlation between CELA3B expression levels and the degree of tumor differentiation suggests that CELA3B could serve as a molecular marker for assessing acinar cell carcinoma differentiation status, which may have implications for treatment strategies and outcome prediction .

What are the technical challenges in optimizing CELA3B antibody staining?

Several technical factors can impact CELA3B antibody staining quality and consistency:

• Fixation variables: Over-fixation or under-fixation of tissue samples can affect antigen preservation and accessibility

• Antigen retrieval optimization: The specific pH (7.8) and temperature (121°C) conditions are critical for exposing CELA3B epitopes

• Antibody dilution: The recommended 1:1800 dilution must be carefully optimized for each laboratory's specific conditions

• Tissue heterogeneity: Variability in CELA3B expression within tumors necessitates examining multiple tissue sections

• Cross-reactivity considerations: The rare positivity in salivary gland tumors must be accounted for when interpreting results

Researchers should conduct careful validation studies when implementing CELA3B immunohistochemistry in new laboratory settings .

How does the performance of CELA3B antibody compare with other acinar differentiation markers?

While CELA3B demonstrates excellent specificity (99.9%) for acinar cell carcinoma, its sensitivity (75%) indicates that it should be used as part of a panel of acinar differentiation markers. Complementary markers include:

• Carboxypeptidase A1 (CPA1): Shows significant correlation with CELA3B expression

• Chymotrypsin: Another pancreatic enzyme marker

• Trypsin: Used for detecting acinar differentiation

• Bcl10: Can help identify acinar cell carcinoma

Could CELA3B antibody be utilized in studying pancreatic development and differentiation?

CELA3B's highly specific expression pattern makes it a potentially valuable tool for studying pancreatic development and differentiation processes. Researchers could utilize CELA3B antibody to:

• Track acinar cell differentiation during embryonic development

• Evaluate differentiation status in pancreatic organoid models

• Monitor acinar-to-ductal metaplasia in disease models

• Assess the impact of genetic manipulations on pancreatic cell type specification

The antibody's ability to clearly delineate acinar cells from other pancreatic cell types provides an opportunity to investigate developmental pathways and differentiation mechanisms in both normal and pathological contexts .

What is known about the relationship between CELA3B detection in stool and pancreatic function?

CELA3B is clinically used to assess exocrine pancreatic insufficiency through stool tests. The protein is resistant to proteolytic degradation during intestinal transit and can be detected in high concentrations in stool. Commercial assays such as the ScheBo Pancreatic Elastase 1 Stool Test utilize ELISA technology to detect CELA3B in stool samples, providing a non-invasive method for evaluating pancreatic exocrine function .

This application extends the utility of CELA3B beyond tissue-based diagnostics to functional assessment of the pancreas, which could be particularly relevant for research on pancreatic insufficiency, chronic pancreatitis, and related conditions .

How might CELA3B antibody be incorporated into multi-parameter tissue analysis methods?

Emerging research techniques offer opportunities to incorporate CELA3B antibody into more sophisticated tissue analysis methods:

• Multiplex immunofluorescence: Combining CELA3B with other markers (e.g., CPA1, Ki-67, neuroendocrine markers) to simultaneously visualize multiple cellular features

• Mass cytometry imaging: Utilizing metal-conjugated CELA3B antibodies for highly multiplexed tissue imaging

• Spatial transcriptomics: Correlating CELA3B protein expression with gene expression profiles in the same tissue regions

• Digital pathology: Employing machine learning algorithms to quantify CELA3B staining patterns across whole slide images

These advanced applications could provide deeper insights into the biology of pancreatic tumors and potentially reveal new subclassifications with clinical relevance .